Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels
- PMID: 17014998
- DOI: 10.1016/j.ejps.2006.08.004
Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels
Abstract
This study presents the development and evaluation of a feedback turnover model that mimics drug-induced effects on brain extracellular levels of serotonin (5-HT) after acute administration of the selective serotonin reuptake inhibitor (SSRI) escitalopram (S-citalopram) in rats. The extracellular 5-HT output in the hippocampus was continuously monitored by intracerebral microdialysis in conjunction with serial arterial blood sampling for evaluation of escitalopram pharmacokinetics. 5-HT levels were significantly increased following administration of 2.5, 5 and 10 mg/kg of escitalopram and the 5-HT levels gradually declined to its baseline value within 360 min. However, at 5 and 10 mg/kg, the response-time curves were almost identical. This might be explained by activation of serotonergic autoreceptors exerting negative feedback, leading to a reduced release of new 5-HT into the synapse. The dynamics of escitalopram-evoked changes of 5-HT response was characterized by a turnover model, which included an inhibitory feedback moderator component. Thus, the response acted linearly on the production of the moderator, which acted inversely on the production of response. The plasma kinetics served as input to an inhibitory function acting on the loss of response. Simultaneous fitting of the model after three constant rate infusions demonstrated the flexibility of the system. The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml. In conclusion, the model lends itself to 'what-if' predictions at different drug exposure scenarios, and has potential for extrapolation of the pharmacodynamics of SSRIs in man.
Similar articles
-
Pharmacokinetic/pharmacodynamic feedback modelling of the functional corticosterone response in rats after acute treatment with escitalopram.Basic Clin Pharmacol Toxicol. 2007 Mar;100(3):182-9. doi: 10.1111/j.1742-7843.2006.00029.x. Basic Clin Pharmacol Toxicol. 2007. PMID: 17309522
-
An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents.J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):214-23. doi: 10.1016/j.vascn.2006.07.001. Epub 2006 Aug 4. J Pharmacol Toxicol Methods. 2007. PMID: 16990018
-
[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Encephale. 2007. PMID: 18789789 Review. French.
-
Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. doi: 10.1017/S1461145705006462. Epub 2006 Feb 1. Int J Neuropsychopharmacol. 2007. PMID: 16448580
-
Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies.Fundam Clin Pharmacol. 1996;10(1):16-27. doi: 10.1111/j.1472-8206.1996.tb00145.x. Fundam Clin Pharmacol. 1996. PMID: 8900496 Review.
Cited by
-
Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):497-512. doi: 10.1007/s10928-013-9325-1. Epub 2013 Jul 4. J Pharmacokinet Pharmacodyn. 2013. PMID: 23824920
-
Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions.J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):1-24. doi: 10.1007/s10928-010-9172-2. Epub 2010 Nov 4. J Pharmacokinet Pharmacodyn. 2011. PMID: 21046209 Free PMC article.
-
Clinical implications of genetic variation in the serotonin transporter promoter region: a review.Prim Care Companion J Clin Psychiatry. 2009;11(3):93-102. doi: 10.4088/pcc.08r00656. Prim Care Companion J Clin Psychiatry. 2009. PMID: 19617941 Free PMC article.
-
Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.Int J Neuropsychopharmacol. 2014 Oct 31;18(4):pyu063. doi: 10.1093/ijnp/pyu063. Int J Neuropsychopharmacol. 2014. PMID: 25522403 Free PMC article. Clinical Trial.
-
Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders.J Neurosci. 2010 Oct 27;30(43):14482-9. doi: 10.1523/JNEUROSCI.2409-10.2010. J Neurosci. 2010. PMID: 20980606 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical